Pancreatic Cancer to be Focus of AACR Conference in New Orleans
NEW ORLEANS — The American Association for Cancer Research (AACR) will release new data on pancreatic cancer mortality rates along with clinical research on promising new treatment options at its special conference on Pancreatic Cancer: Innovations in Research and Treatment, May 18-21, at the Hyatt Regency New Orleans.
A press kit containing releases and highlighted abstracts will be available May 13. Research that will be highlighted in the conference includes:
- New analyses projecting paradigm-shifting pancreatic cancer mortality rates;
- Updated results of a phase Ib trial combining gemcitabine with a new radioimmunotherapy for metastatic pancreatic cancer;
- Development and validation of a blood-based biomarker panel for detection of early-stage pancreatic cancer; and
- Preclinical results indicating CD47 may be a therapeutic target for pancreatic neuroendocrine tumors and pancreatic ductal adenocarcinoma.
The aim of the conference is to provide insight on recent advances in pancreatic cancer, ranging from genomics to the new technologies rapidly changing approaches to prevention, diagnosis, and treatment.
Read the online program.